Odonate an­nounces 'pos­i­tive' re­sults but faces in­vestor back­lash; Aslan is once again re­cruit­ing clin­i­cal tri­al par­tic­i­pants af­ter months-long wait amid the pan­dem­ic

Odonate Ther­a­peu­tics an­nounced “pos­i­tive top-line re­sults” from a Phase III study of their lead can­cer drug. And sure enough, tese­tax­el im­proved pro­gres­sion-free sur­vival for metasta­t­ic breast can­cer pa­tients over place­bo by 2.9 months.

But in­vestors al­so ap­peared to see some­thing else: a 71% rate of neu­trope­nia for pa­tients in the treat­ment arm, vs. a 8.3% rate for the con­trol group, who re­ceived the gener­ic chemother­a­py capecitabine. The Phase III study cov­ered 685 pa­tients.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN